NPI registry status
Active
2026 NPPES data Research Study Specialist NPI 1831159649 MD
Verify on CMS → Anthony Szema, MD
Research Study Specialist in South Setauket, New York.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 508 in Research Study Specialist, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
417
Medicare Part D claims · 132 beneficiaries · Research Study Specialist avg: 922
Generic prescribing
45%
generic claims · 55% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$39.86
1 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Anthony Szema, MD filed 417 Medicare Part D claims in 2024 as a Research Study Specialist in South Setauket, New York, prescribing 45% generic.
- 417
- Part D claims, 2024
- 45%
- generic prescribing
- $39.86
- industry payments (Sunshine Act)
- ≥61st
- pct by Part D claim volume (lower-bound band)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Anthony Szema, MD
Federal records show an active NPI with Medicare Part D prescribing activity — verifiable registry data, not a proprietary rating.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1831159649), first enumerated 03/24/2006.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 417 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
Hospital affiliations
1 CMS Care Compare hospital affiliation on record — practice footprint from the Doctors and Clinicians file.
Source: CMS Care Compare
- Reported
Industry payment transparency
$39.86 in reported industry payments (1 transfers) in 2024 under the federal Sunshine Act — disclosed transfers of value, not a quality rating.
Source: CMS Open Payments
- State context
State board disciplinary context
New York statewide board action statistics are published annually — these figures describe aggregate state activity, not Anthony Szema, MD's individual license status. Verify directly with the state medical board.
Source: NYSBPMC annual report 2023
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1831159649 · Research Study Specialist
NPI-10 · ENUM-LEGACY · TAX-NARROW · RX-LIGHT · BOOK-THIN · PHOTO-ENUM
- NPI-10 1831159649
- ENUM-LEGACY 2006
- TAX-NARROW 508
- RX-LIGHT 417
- BOOK-THIN 31 in New York
- PHOTO-ENUM David Cummings · 2006
Anthony Szema, MD's Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2024, across all CMS prescribers nationally
417 ≥ 61st percentile 61% of 1,416,883 prescribers are in lower value bands
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative 100-claim band: it counts only prescribers in lower claim-volume bands. Medicare Part D claim volume is activity context, not a quality measure or recommendation. See methodology § corpus placement.
Source CMS Medicare Part D Prescriber Public Use File · 2024
What does the federal data show about Anthony Szema, MD?
Quality data not reportedPrimary specialty
Research Study Specialist
Medicare Part D claims
417 55% vs specialty avg
Specialty distribution in New York
How Research Study Specialist compares to other specialties among New York providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Research Study Specialist. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1831159649 |
|---|---|
| Specialty | Research Study Specialist |
| Credentials | MD |
| Gender | Male |
| NPI Issued | 03/24/2006 |
Hospital and facility affiliations
Facilities where Anthony Szema, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Three Village Allergy And Asthma, PLLC
South Setauket, NY
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Anthony Szema, MD. Source: openpaymentsdata.cms.gov.
Total received
$40
Largest payer
GlaxoSmithKline, LLC.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - New York NYSBPMC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 - they are NOT specific to Anthony Szema, MD. To verify Anthony Szema, MD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
Anthony Szema, MD - brand share 55.0%
Research Study Specialist average
55% brand-name claims vs 45% generic, on 417 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
417
Total Claims
$1.9M
Total Drug Cost
132
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 783.9
- Total Day Supply
- 21,330
- Brand vs Generic
- 55% brand / 45% generic
- Brand Drug Cost
- $1.3M
- Generic Drug Cost
- $596K
Patient Demographics
- Average Patient Age
- 72.5 years
- Avg HCC Risk Score
- 1.21
- Gender Split
- 70% female / 30% male
- Age Distribution
- <65: 15, 65-74: 61, 75-84: N/A, 85+: N/A
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Anthony Szema, MD prescribes most
Top Medicare Part D drugs by claim count, 2024
- Epinephrine
Epinephrine
85 claims
- Albuterol Sulfate …
Albuterol Sulfate Hfa
42 claims
- Trelegy Ellipta
Trelegy Ellipta
40 claims
- Ipratropium Bromide 24
Ipratropium Bromide
24 claims
- Fasenra 20
Fasenra
20 claims
- Prednisone 16
Prednisone
16 claims
- Montelukast Sodium 14
Montelukast Sodium
14 claims
- Takhzyro 14
Takhzyro
14 claims
| Drug | Claims |
|---|---|
| Epinephrine | 85 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 42 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 40 |
| Ipratropium Bromide | 24 |
| Fasenra Benralizumab | 20 |
| Prednisone | 16 |
| Montelukast Sodium | 14 |
| Takhzyro Lanadelumab-Flyo | 14 |
| Xolair Omalizumab | 14 |
| Dupixent Syringe Dupilumab | 13 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Research Study Specialist Overview
How Anthony Szema, MD fits within the Research Study Specialist landscape nationally.
508
Research Study Specialist Providers in US
42
States with Research Study Specialist
922
Avg Claims per Provider
Anthony Szema, MD's 417 claims are below the specialty average of 922.
Nationwide Research Study Specialist peers with similar MIPS or enrollment year
Two federal-record peer sets for Szema, both outside New York so the neighborhoods are not geographic containment.
Same NPPES enumeration year (2006)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Research Study Specialist Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as Szema.
One of 31 Research Study Specialist providers enrolled in New York, 5 are shown here.
Dr. Alen Agaronov
SCD, RDN
New York, NY
Dr. Aries Arditi
PHD
Chappaqua, NY
Stephanie Belizaire
Rosedale, NY
Collette Bent
Queens Village, NY
Dr. Kuldeep Bhargava
PHD
New Hyde Park, NY
Compare Research Study Specialist nationally: see state-by-state distribution →
Frequently Asked Questions
What is Anthony Szema, MD's specialty? ▼
Anthony Szema, MD specializes in Research Study Specialist and practices in South Setauket, New York. Credentials: MD.
How much does Anthony Szema, MD prescribe under Medicare Part D? ▼
In 2024, Anthony Szema, MD wrote 417 Medicare Part D claims totaling $1.9M in drug costs for 132 beneficiaries.
Where is Anthony Szema, MD located? ▼
Anthony Szema, MD is located at 3771 NESCONSET HWY, South Setauket, NY, 11720. Phone: (631) 675-6474.
What is Anthony Szema, MD's NPI number? ▼
Anthony Szema, MD's National Provider Identifier (NPI) is 1831159649, issued on 03/24/2006.
Does Anthony Szema, MD prescribe more brand-name or generic drugs? ▼
Anthony Szema, MD's prescribing is 55% brand-name and 45% generic drugs by claim count, with $1.3M in brand drug costs.
How many Research Study Specialist providers are there in the US? ▼
There are 508 Research Study Specialist providers across 42 states in the US. The average Research Study Specialist provider writes 922 Medicare Part D claims per year.
What drugs does Anthony Szema, MD prescribe most often? ▼
Based on 2024 Medicare Part D data, Anthony Szema, MD's most frequently prescribed drugs include Epinephrine, Albuterol Sulfate Hfa, Trelegy Ellipta. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Anthony Szema, MD accept Medicare? ▼
Anthony Szema, MD appears in CMS Medicare data with 417 Part D claims and 132 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Anthony Szema, MD's credentials? ▼
Anthony Szema, MD's NPI is 1831159649 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.